Cargando…
Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available. For those with first-episode psychosis, all licensed antipsychotic medications act via dopamine...
Autores principales: | Chesney, Edward, Oliver, Dominic, McGuire, Philip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110455/ https://www.ncbi.nlm.nih.gov/pubmed/34255100 http://dx.doi.org/10.1007/s00213-021-05905-9 |
Ejemplares similares
-
Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022) -
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
por: Englund, Amir, et al.
Publicado: (2022) -
Cannabidiol (CBD) in Cancer Management
por: O’Brien, Kylie
Publicado: (2022) -
Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
por: Chesney, Edward, et al.
Publicado: (2020) -
Towards Better Delivery of Cannabidiol (CBD)
por: Millar, Sophie Anne, et al.
Publicado: (2020)